中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2014年
5期
301-306
,共6页
陈伶俐%谭云山%曾海英%侯英勇%许建芳%赵婧%纪元
陳伶俐%譚雲山%曾海英%侯英勇%許建芳%趙婧%紀元
진령리%담운산%증해영%후영용%허건방%조청%기원
肝肿瘤%增生%预后
肝腫瘤%增生%預後
간종류%증생%예후
Liver neoplasms%Hyperplasia%Prognosis
目的:探讨肝脏异型增生结节( DN)癌变过程中的病理形态变化,明确DN和早期肝细胞癌( eHCC)患者预后的关系。方法收集上海中山医院2000至2009年间所有诊断为DN或eHCC或高分化HCC的手术切除标本145例,应用肝细胞肿瘤国际共识小组( ICGHN )2008年对DN和eHCC的诊断标准复片,并用免疫组织化学EnVision法检测CD34、热休克蛋白(HSP)70、谷氨酰胺合成酶( GS)、磷脂酰肌醇蛋白聚糖3( GPC3)、Ki-67在所有病例中的表达。比较前后2次诊断结果并结合患者随访资料进行预后生存分析。结果(1)145例标本中,原病理诊断为DN 96例,eHCC 49例,进展期HCC 0例;按现有病理标准诊断为 DN 66例,其中低级别 DN ( LGDN )16例,高级别 DN (HGDN)50例,eHCC 72例,进展期HCC 7例;与原病理诊断一致的有112例(77.2%),与原病理诊断不一致的有33例(22.8%),均为诊断不足,进展期HCC诊断为HGDN或eHCC 7例,eHCC诊断为HGDN 26例。(2)DN患者(41例)和eHCC患者(64例)总体生存率(P=0.778)及无瘤生存率(P=0.949)差异均无统计学意义;伴进展期HCC的DN或eHCC患者(40例)与不伴进展期HCC的DN或eHCC患者(51例)总体生存率差异有统计学意义(P=0.004),但无瘤生存率差异无统计学意义(P=0.079);在首次发现且不伴进展期 HCC 的 DN 患者(16例)和 eHCC 患者(35例)总体生存率(P=0.677)和无瘤生存率(P=0.700)差异均无统计学意义。结论应用ICGHN的DN和eHCC病理诊断标准可以较好地发现和诊断DN和eHCC病例。经手术切除的DN和eHCC患者预后无差异。DN和eHCC患者预后较进展期HCC好,但与进展期HCC有同等复发危险。
目的:探討肝髒異型增生結節( DN)癌變過程中的病理形態變化,明確DN和早期肝細胞癌( eHCC)患者預後的關繫。方法收集上海中山醫院2000至2009年間所有診斷為DN或eHCC或高分化HCC的手術切除標本145例,應用肝細胞腫瘤國際共識小組( ICGHN )2008年對DN和eHCC的診斷標準複片,併用免疫組織化學EnVision法檢測CD34、熱休剋蛋白(HSP)70、穀氨酰胺閤成酶( GS)、燐脂酰肌醇蛋白聚糖3( GPC3)、Ki-67在所有病例中的錶達。比較前後2次診斷結果併結閤患者隨訪資料進行預後生存分析。結果(1)145例標本中,原病理診斷為DN 96例,eHCC 49例,進展期HCC 0例;按現有病理標準診斷為 DN 66例,其中低級彆 DN ( LGDN )16例,高級彆 DN (HGDN)50例,eHCC 72例,進展期HCC 7例;與原病理診斷一緻的有112例(77.2%),與原病理診斷不一緻的有33例(22.8%),均為診斷不足,進展期HCC診斷為HGDN或eHCC 7例,eHCC診斷為HGDN 26例。(2)DN患者(41例)和eHCC患者(64例)總體生存率(P=0.778)及無瘤生存率(P=0.949)差異均無統計學意義;伴進展期HCC的DN或eHCC患者(40例)與不伴進展期HCC的DN或eHCC患者(51例)總體生存率差異有統計學意義(P=0.004),但無瘤生存率差異無統計學意義(P=0.079);在首次髮現且不伴進展期 HCC 的 DN 患者(16例)和 eHCC 患者(35例)總體生存率(P=0.677)和無瘤生存率(P=0.700)差異均無統計學意義。結論應用ICGHN的DN和eHCC病理診斷標準可以較好地髮現和診斷DN和eHCC病例。經手術切除的DN和eHCC患者預後無差異。DN和eHCC患者預後較進展期HCC好,但與進展期HCC有同等複髮危險。
목적:탐토간장이형증생결절( DN)암변과정중적병리형태변화,명학DN화조기간세포암( eHCC)환자예후적관계。방법수집상해중산의원2000지2009년간소유진단위DN혹eHCC혹고분화HCC적수술절제표본145례,응용간세포종류국제공식소조( ICGHN )2008년대DN화eHCC적진단표준복편,병용면역조직화학EnVision법검측CD34、열휴극단백(HSP)70、곡안선알합성매( GS)、린지선기순단백취당3( GPC3)、Ki-67재소유병례중적표체。비교전후2차진단결과병결합환자수방자료진행예후생존분석。결과(1)145례표본중,원병리진단위DN 96례,eHCC 49례,진전기HCC 0례;안현유병리표준진단위 DN 66례,기중저급별 DN ( LGDN )16례,고급별 DN (HGDN)50례,eHCC 72례,진전기HCC 7례;여원병리진단일치적유112례(77.2%),여원병리진단불일치적유33례(22.8%),균위진단불족,진전기HCC진단위HGDN혹eHCC 7례,eHCC진단위HGDN 26례。(2)DN환자(41례)화eHCC환자(64례)총체생존솔(P=0.778)급무류생존솔(P=0.949)차이균무통계학의의;반진전기HCC적DN혹eHCC환자(40례)여불반진전기HCC적DN혹eHCC환자(51례)총체생존솔차이유통계학의의(P=0.004),단무류생존솔차이무통계학의의(P=0.079);재수차발현차불반진전기 HCC 적 DN 환자(16례)화 eHCC 환자(35례)총체생존솔(P=0.677)화무류생존솔(P=0.700)차이균무통계학의의。결론응용ICGHN적DN화eHCC병리진단표준가이교호지발현화진단DN화eHCC병례。경수술절제적DN화eHCC환자예후무차이。DN화eHCC환자예후교진전기HCC호,단여진전기HCC유동등복발위험。
Objective To study the clinical features , pathologic findings and prognosis of patients with dysplastic nodules of liver ( DN ) and early hepatocellular carcinomas ( eHCC ).Methods One hundred and forty-five archival cases previously diagnosed as DN or eHCC or well-differentiated HCC during the period from 2000 to 2009 were retrieved and reevaluated with the new diagnostic criteria by two experienced pathologists , according to International Consensus Group for Hepatocellular Neoplasia ( ICGHN) 2008.Immunohistochemical study (EnVision method) for CD34, HSP70, glutamine synthetase, glypican 3 and Ki-67 was carried out.The original diagnosis and diagnosis after review were compared and correlated with the survival data of the patients , with statistical analysis.Results With the new criteria , 16 cases were diagnosed as low-grade DN, 50 cases as high-grade DN, 72 cases as DN with microinvasion , 7 cases as advanced HCC.Slide review showed no diagnostic discrepancy in 112 cases ( 77.2%).Amongst the 33 (22.8%) underdiagnosed cases , there were 7 cases of advanced HCC initially diagnosed as DN or DN with microinvasion and 26 cases of eHCC initially diagnosed as high-grade DN.Kaplan-Meier analysis showed that the diagnosis of high-grade DN or early HCC carried no statistically significant difference in overall survival (P=0.778, 0.677) or disease-free survival (P=0.949, 0.700) in all patients and in patients with no history of HCC.The co-existence of advanced HCC in patients with DN or eHCC significantly correlated with overall survival (P=0.004) but not with disease-free survival (P=0.079).Conclusions The new diagnostic criteria by ICGHN 2008 are useful in delineating high-grade DN and eHCC.The overall survival and disease-free survival of patients with eHCC or high-grade DN undergoing hepatectomy show no statistically significant difference.Patients with DN or eHCC have better prognosis than patients with advanced HCC , though there is still a high risk of tumor recurrence .